Sign In
Buy IKT
$1.70
-0.0100 (-0.585%)
At Close: Jun 02, 2026
Inhibikase: Potential To Improve Current Treatment Options For PAH Patients
01:32pm, Tuesday, 19'th Nov 2024
The company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
08:37am, Thursday, 14'th Nov 2024
-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hyp
-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60�
-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeuti
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
06:13pm, Thursday, 15'th Aug 2024
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q2 2024 Earnings Conference Call August 15, 2024 8:00 AM ET Company Participants Alexander Lobo - Precision AQ, Investor Relations Milton Werner - President
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
04:25pm, Wednesday, 14'th Aug 2024
BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor t
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
08:00am, Wednesday, 07'th Aug 2024
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease
08:05am, Monday, 17'th Jun 2024
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
08:05am, Wednesday, 05'th Jun 2024
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase
Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
09:57pm, Friday, 17'th May 2024
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2024 Earnings Conference Call May 16, 2024 8:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Milton Werner - CEO Garth Lees-Rolfe
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
08:00pm, Wednesday, 15'th May 2024
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
08:45am, Wednesday, 15'th May 2024
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
08:00am, Thursday, 09'th May 2024
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension –
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
04:30pm, Thursday, 18'th Apr 2024
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor
